We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
JDT, yep completely agree but still, what is stated in an RNS has to be factual. If situations change which make the information within said RNS no longer factual then a new RNS should be released to clarify the new facts!
HappyDays. Here's a snippet from the BAMS RNS 22nd July on CONDOR acceptance:
So it was with them from end July - he sold in Oct. COVID is a moving goalpost - what's not to say in Oct he was under the impression it was nearly there....then new variants / govt strategy changes etc etc forced them back to the drawing board?
"The work with the CONDOR programme will commence immediately to evaluate the test performance using real patient samples and will quickly progress to full clinical validation.
Dr. Alastair Smith, Chief Executive of Avacta Group commented:
"I am delighted that the COVID-19 BAMS assay that we are developing with Adeptrix has been accepted into the CONDOR programme. This provides us with access to patient samples and partners in UK hospitals to rapidly carry out the validation studies that are critical to progress the BAMS assay development."
I have sold out at a small loss today (actually I do still have a tiny amount left in my SIPP). I am sure that avact will one day be a great investment but I, like many others am very frustrated with the delay on Covid tests. It is Feb 2021. I appreciate the arguments that covid is not entirely going away but I would suspect that this time next year test demand will be a fraction that it is today.
SNG is the no brainer covid stock for me followed by NCYT (although this is priced in somewhat).
I will look to buy back in to Avact when there is no covid premium in the sp. I suggest under 80p but hard to value.
Nb - watch this start shooting up now and me madly panic to buy back my shares at a premium.
JDT, I don't know it but I do know at that time we all thought the validation that we were told would be complete at the end of summer, was just taking a bit longer than expected so far to presume S&S numbers could / should drop any day.
Sadly its much more logically likely that AS knew that they were not in a position to even start validation let alone have it completed. Sorry, I have always defended the guy passionately but this should have been put in an RNS! Oh hang on that will drop the SP, and me and the Mrs want a new house....it does not look or small good.
HappyDays "He knew it was miles off and withheld that information to fill his own pockets....seriously bad!!!"
And you know that how?
Ndn71 maybe you should sell your not happy if you hold that is
We do have to face facts that AS words
"to further develop the potential for the BAMS COVID-19 test" are not good to hear when the market was expecting "exquisite" S&S figures and confirmation that BAMS is fantastic, and ready to be sold in the masses.
I'm holding for the long term so yes another big player on board is good but can't butter this RNS up as being more good news than bad...its mostly bad!
Yet another big delay, AS integrity in serous doubt. The time he cashed in nearly half a million quid we were all believing from his words that BAMS was about to be on the market any day. He knew it was miles off and withheld that information to fill his own pockets....seriously bad!!!
I read the RNS in a negative way until it was noticed that they’re developing an in-house pipeline of Affimer-based diagnostic assays including the AffiDXTM SARS-CoV-2 Lateral Flow Rapid Antigen Test and a BAMSTM SARS-CoV-2 Assay in partnership with Adeptrix Inc.
Bruker is one of the world's foremost suppliers of mass spectrometers with a significant installed base in clinical microbiology laboratories in hospitals world-wide.
Bruker will have consulted with its current customers to establish potential BAMS take up worldwide! Answer: Massive!
Avacta, has been working with its clinical partners in the UK to refine the assay to fit into the typical workflows in a clinical microbiology laboratory.
Bruker must have asked the question “ how is BAMS doing in the Avacta and Falcon C19 evaluations?” Answer: “Well enough for UK gov to want to implement BAMS in UK hospitals and potentially buy some MALDI-TOF instruments. Highly likely Europe will follow suit”
The collaboration will
...... assess the suitability of the test as a professional-use in-vitro diagnostic (IVD) product for SARS-CoV-2 infection to run on Bruker's MALDI-TOF instruments for sale in the UK and Europe.
........ further develop the potential for the BAMS COVID-19 test as a clinical IVD.
...... clinical assessment of the BAMS assay on Bruker's MALDI-TOF instruments.
Sales of the BAMS assay AND Bruker MALDI-TOF instruments will be significant hence the collaboration. Both parties already know this will happen soon!
"The collaboration with Bruker announced today will assess the suitability of the test as a professional-use in-vitro diagnostic (IVD) product for SARS-CoV-2 infection to run on Bruker's MALDI-TOF instruments for sale in the UK and Europe."
States "will assess the suitability of the test...". In other words there is a test but can we bring it to the market? Be fore you all jump on me as a deramper, I still hold even after selling part of my investment after Sir Al's house buying spree. This is a very poor uninformative RNS and they would probably have been better off not issuing it after the Abingdon debacle yesterday.